InvestorsHub Logo
Post# of 252218
Next 10
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: DewDiligence post# 212458

Wednesday, 07/19/2017 4:49:47 PM

Wednesday, July 19, 2017 4:49:47 PM

Post# of 252218
SRPT:

This settlement led to the launch of their named patient expanded access program this morning.

http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2287336
http://www.sarepta.com/community/managed-access-program

On the call they said not to expect meaningful revenue till Q4 still I like the aggressive nature of the new CEO.

The guidance for the year increased to 125-130 is still pretty low IMO it would imply 75-80M for Q3+Q4 which is basically no growth given the number of patients now on drug. Granted summer months may have slower uptake perhaps some more missed doses but I think they are (continuing to be) conservative.

This is the afternoon Earnings PR
http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2287336

The call is available here:
http://edge.media-server.com/m/p/tmiout8w/lan/en

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.